"Groundbreaking Research: Monoclonal Antibodies Tame Aggressive Prostate and Breast Cancers"

Experimental monoclonal antibodies have shown promise in sensitizing aggressive prostate and breast cancers to treatment. By blocking the interaction between growth factor VEGF and its receptor neuropilin-2, these antibodies render the tumors susceptible to immunotherapy. In mouse models, the antibodies successfully activated anti-tumor immunity and inhibited tumor growth. The approach could potentially change the fate of patients with relapsed or treatment-resistant cancers. However, further research is needed to determine the effectiveness of these antibodies in human clinical trials.